Michael Mendelsohn Net Worth

Michael Mendelsohn biography

Dr. Michael E. Mendelsohn M.D. serves as Independent Director of the Company. He has served as a member of our Board of Directors since we commenced operations as an independent company in April 2019. Dr. Mendelsohn has been the executive chairman and president of Cardurion Pharmaceuticals since May 2016 and is the president of the Mendelsohn Consulting Group LLC, which he formed in September 2013. Since April 2015, Dr. Mendelsohn has been a senior advisor and consultant to the chief medical and scientific officer of Takeda Pharmaceutical Co. Ltd. and, since December, 2014, has served as senior advisor and consultant and a member of the pharmaceuticals advisor committee for the chief scientific officer and president of R&D at Ironwood. From May 2014 until July 2017, Dr. Mendelsohn was a venture partner for SV Health Investors. Prior to that, Dr. Mendelsohn was the senior vice president and global head of cardiovascular research at Merck Research Laboratories from June 2010 to November 2013. From 1993 to 2010, Dr. Mendelsohn served in various roles at Tufts Medical Center and Tufts University School of Medicine, including as founder and executive director of the Molecular Cardiology Research Institute and as chief scientific officer from 2008 to 2010. Previously, Dr. Mendelsohn was a member of the cardiovascular faculty at Brigham and Women’s Hospital and Harvard Medical School. Dr. Mendelsohn serves as a director of Foghorn Therapeutics, Inc. and previously served on the board of directors of Regado Biosciences Inc. from November 2013 to May 2015. Dr. Mendelsohn received a B.A. in chemistry and English from Amherst College and a M.D. from Harvard Medical School.

What is the salary of Michael Mendelsohn?

As the Independent Director of Cyclerion Therapeutics, the total compensation of Michael Mendelsohn at Cyclerion Therapeutics is $140,753. There are 10 executives at Cyclerion Therapeutics getting paid more, with Andreas Busch having the highest compensation of $3,251,110.

How old is Michael Mendelsohn?

Michael Mendelsohn is 65, he's been the Independent Director of Cyclerion Therapeutics since 2019. There are 2 older and 12 younger executives at Cyclerion Therapeutics. The oldest executive at Cyclerion Therapeutics, Inc. is George Conrades, 81, who is the Independent Director.

What's Michael Mendelsohn's mailing address?

Michael's mailing address filed with the SEC is 500 TECHNOLOGY SQUARE, STE 700, CAMBRIDGE, MA, 02139.

Insiders trading at Cyclerion Therapeutics

Over the last 6 years, insiders at Cyclerion Therapeutics have traded over $240,273 worth of Cyclerion Therapeutics stock and bought 4,653,203 units worth $33,009,775 . The most active insiders traders include Peter M Hecht, Mark G Currie, and Terrance Mcguire. On average, Cyclerion Therapeutics executives and independent directors trade stock every 84 days with the average trade being worth of $749,841. The most recent stock trade was executed by Terrance Mcguire on 9 August 2023, trading 8 units of CYCN stock currently worth $27.

What does Cyclerion Therapeutics do?

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics executives and stock owners

Cyclerion Therapeutics executives and other stock owners filed with the SEC include:

• Andreas Busch,
  Chief Innovation Officer, Head of the Innovation Center
• Dr. Andreas Busch Ph.D.,
  Chief Scientific Officer
• Mark Currie,
  President, Chief Scientific Officer
• Marsha Fanucci,
  Independent Chairman of the Board
• Terrance McGuire,
  Independent Director
• Amy Schulman,
  Independent Director
• George Conrades,
  Independent Director
• Stephanie Lovell,
  Independent Director
• Ole Isacson,
  Independent Director
• Kevin Churchwell,
  Independent Director
• Michael Mendelsohn,
  Independent Director
• Peter Hecht,
  Chief Executive Officer, Director
• Dr. Peter M. Hecht Ph.D.,
  CEO, Interim CFO, Principal Accounting Officer & Director
• William Huyett,
  Chief Financial Officer
• Jennifer Chickering,
  Sr. Director of Clinical Strategy
• Christopher Winrow,
  Sr. Director of Clinical Devel. & Neuroscience Program Lead
• Jessica Rennekamp,
  Associate Director of Corp. Communications
• Dr. Todd Milne Ph.D.,
  VP of Corp. Devel.
• Cheryl Gault,
  Chief Operating Officer
• Anjeza Gjino,
  CFO & Corp. Sec. (Maternity Leave of Absence)
• Regina Margaret Graul,
  See Remarks
• Path Capital Lp Greenspan D...,
  
• Christopher I Wright,
  Chief Medical Officer
• Anjeza Gjino,
  Chief Financial Officer
• Errol B Desouza,
  
• Pharmaceuticals Inc Ironwood,
  10% owner
• Cheryl Gault,
  Chief Operating Officer
• Steven Hyman,